Small cell carcinoma of the vagina is rare, so rare in fact that the total number reported in English-language journals is less than 30. Due to this extremely low incidence, no specific treatment guidelines have been established, and most of what is clinically known is derived from a handful of single case reports. However, as befitting its highly aggressive histologic features, which are reminiscent of
small cell lung cancer (SCLC), first-line treatment is modeled after SCLC. Herein is reported the case of a 51-year-old African-American patient with metastatic biopsy-proven
small cell carcinoma of the vagina that progressed through multiple
therapies: first-line
cisplatin and
etoposide (making it
platinum-resistant) and
radiotherapy, followed by the
tumor macrophage-stimulating agent
RRx-001 in a clinical trial called QUADRUPLE THREAT, which per protocol preceded a mandated rechallenge with
cisplatin and
etoposide. RECIST v.1.1
tumor progression on both
RRx-001 and
cisplatin/
etoposide was accompanied by central
necrosis in several of the enlarged lymph nodes and hepatic
metastases, which may have been evidence of pseudoprogression, accounting for her ongoing longer-than-expected survival, since the necrotic tissue may have primed the activity of the
PD-1 inhibitor. The lack of response to
RRx-001 is hypothesized to have correlated with sparse
tumor macrophage infiltration, seen on pre- and post-treatment biopsies, since the mechanism of action of
RRx-001 relates to stimulation of tumor-associated macrophages.